Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00151632
Other study ID # AFSSAPS 030200
Secondary ID PHRC/01-01CIC020
Status Terminated
Phase Phase 3
First received September 8, 2005
Last updated July 3, 2012
Start date May 2003
Est. completion date May 2009

Study information

Verified date July 2012
Source Rennes University Hospital
Contact n/a
Is FDA regulated No
Health authority France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study type Interventional

Clinical Trial Summary

The prevention of graft rejection after liver transplantation benefits nowadays from a variety of newly developed immunosuppressive agents. This allows more flexible and individualized immunoprophylaxis and gives an opportunity to reduce the long-term side effects (hypertension, renal failure, diabetes, etc.) of immunosuppression. The purpose of this study is to evaluate, in liver transplanted patients, if low doses of tacrolimus, given in combination with mycophenolate mofetil, can result in a lower rate of long-term side effects without increasing the rate of graft rejection.


Description:

Tacrolimus and mycophenolate mofetil are currently approved immunosuppressive agents for the prevention of acute and chronic rejection in liver transplantation. Adverse effects of tacrolimus are dose-dependent and appear early after the onset of treatment. To prevent side effects, we propose to combine reduced doses of tacrolimus with another immunosuppressant, i.e. mycophenolate mofetil, administered at usual doses. This study evaluates the interest of this combination and, subsequently, the pharmacokinetics of mycophenolate mofetil in this therapeutic context. Patients undergoing liver transplantation will be randomized to tacrolimus at normal doses or to the combination of tacrolimus at half doses and mycophenolate mofetil. A corticotherapy will be associated in both groups. The safety will be evaluated on the number of graft rejections between day 1 after transplantation and week 48; the onset of complications (hypertension, renal failure, diabetes, etc.) will allow to evaluate the efficacy of both treatment schedules.


Recruitment information / eligibility

Status Terminated
Enrollment 195
Est. completion date May 2009
Est. primary completion date December 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adults over 18 years of age

- Primary liver transplantation

- Immunosuppressive treatment associating tacrolimus and steroids at low doses (< 20 mg/d)

- Written informed consent

Non-Inclusion Criteria:

- Pregnancy or ineffective contraception

- Immunosuppressive treatment

- Blood group incompatibility with the donor

- Autoimmune hepatitis

- Fulminant hepatitis

- Primary sclerosing cholangitis

- Combined transplantations

- Reduced liver

- Living donor

- Treated hypertension and/or diastolic pressure = 90 mmHg and/or systolic pressure = 140 mmHg,

- Acute or chronic renal failure(creatininemia = 130 µmol/L) before transplantation

- Treated diabetes and/or fasting glycemia = 7 mmol/L

- Treated hypercholesterolemia and/or cholesterolemia = 7 mmol/L

- post-operative creatininemia = 200 µmol/L

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms

  • Evidence of Liver Transplantation

Intervention

Drug:
Mycophenolate mofetil
Mycophenolate mofetil is administered at a dose of 1,5 g x 2 / day for the 6 first weeks, then 1g x 2 / day until M12.
Tacrolimus
In arm 1: Tacrolimus is administered at half recommended dose: 0,040 mg/Kg x 2 , in order to maintain plasma levels between 6 and 10 ng/ml for the 6 first weeks, between 5 and 8 ng/ml from week 7 to M6 and between 4 and 6 ng/ml between M6 and M12. In arm 2: Tacrolimus is administered at the recommended dose: 0,075 mg/Kg x 2 , in order to maintain plasma levels between 12 and 20 ng/ml for the 6 first weeks, between 10 and 15 ng/ml from week 7 to week 12, between 8 and 12 ng/ml between M4 and M6 and between 6 and 10 ng/ml between M6 and M12.

Locations

Country Name City State
France Service de Chirurgie Digestive - Hôpital de la Côte de Nacre Caen
France Service d'Hépatogastroentérologie - Hôpital Beaujon Clichy
France Service d'Hépatogastroentérologie - Hôpital Henri Mondor Créteil
France Chirurgie Générale et Digestive - Hôpital de La Croix Rousse Lyon
France Service d'Hépaogastroentérologie - Hôpital Saint Eloi Montpellier
France Service de Chirurgie Générale - Hôpital Cochin Paris
France Département de Chirurgie Viscérale - Hôpital Pontchaillou Rennes
France Centre Hépato-biliaire - Hôpital Paul Brousse Villejuif

Sponsors (2)

Lead Sponsor Collaborator
Rennes University Hospital Ministry of Health, France

Country where clinical trial is conducted

France, 

References & Publications (2)

Jain AB, Hamad I, Rakela J, Dodson F, Kramer D, Demetris J, McMichael J, Starzl TE, Fung JJ. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. Transplantation. 1998 Nov 27;66(10):1395-8. — View Citation

Klupp J, Glanemann M, Bechstein WO, Platz KP, Langrehr JM, Keck H, Settmacher U, Radtke C, Neuhaus R, Neuhaus P. Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation. Transplant Proc. 1999 Feb-Mar;31(1-2):1113-4. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Onset of acute rejection (criterion evaluating the risk) between Day 1 and Week 48 No
Primary Onset of at least one complication (hypertension, renal failure, diabetes) requiring a specific treatment (criterion evaluating the benefit) between Week 9 and Week 48 Yes
Secondary Onset of hypertension, renal failure, diabetes, hypercholesterolemia, or of a serious adverse effect of mycophenolate mofetil between Day 1 and Week 48 Yes
See also
  Status Clinical Trial Phase
Recruiting NCT02239991 - Management of Perioperative Coagulopathy With Thromboelastometry (ROTEM) in Liver Transplant N/A
Recruiting NCT03013634 - Protective Effects of Dexmedetomidine on Myocardial Injury During Liver Transplantation N/A
Active, not recruiting NCT02579408 - Quantifying Steatosis in Liver Transplant Donors
Completed NCT02008097 - Clinical Benefits of B-Flow Ultrasound N/A
Completed NCT04763096 - Evaluate the Efficacy and Safety of the ADVAGRAF® Phase 4
Recruiting NCT01607788 - Prospective Liver Tumor (ProLiT) Database N/A
Recruiting NCT01766518 - The Study to Evaluate Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients (MYLT1) Phase 4
Not yet recruiting NCT01860716 - Impact of Melatonin in the Pretreatment of Organ Donor and the Influence in the Evolution of Liver Transplant. Phase 3
Completed NCT01022476 - Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients Phase 1/Phase 2
Completed NCT01546064 - Study to Establish Whether the Use of T-Tube in Bile Duct Anastomosis in Liver Transplantation Decreases Morbidity N/A
Completed NCT02263703 - Immunogenicity of HPV Vaccine in Immunosuppressed Children Phase 3
Terminated NCT00473824 - Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation Phase 2
Active, not recruiting NCT02350218 - Safety, Efficacy of Eglandin® in Living Donor Liver Transplanted Patient (PROVISION) Phase 2
Completed NCT02608606 - Determining Equivalence Dose for Oral Versus Sublingual Administration of Tacrolimus in Hepatic Receptors N/A
Recruiting NCT02451046 - Usefulness of Alpha-GST in Liver Transplantation N/A
Completed NCT00177931 - Cefepime Pharmacokinetics in Liver Transplant Recipients in an Intensive Care Unit N/A
Completed NCT01147380 - Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation Phase 1
Terminated NCT00694408 - A Pilot Trial of Pediatric Liver Transplantation Without Steroids Phase 3
Terminated NCT00375895 - Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation Phase 3
Recruiting NCT01157403 - Autologous Transplantation of Mesenchymal Stem Cells for Treatment of Patients With Onset of Type 1 Diabetes Phase 2/Phase 3